“It was pretty clear that we failed.” Chris Hamby and Sheryl Gay Stolberg reveal the backstory to the Covid vaccine production failures in Baltimore. A surprising cast of culprits. The New York Times nytimes.com/2021/12/23/us/…

Emergent BioSolutions was meant to be a pillar of the U.S.’s pandemic plan. Here’s the forgotten history that led to a searing failure. nyti.ms/3ppqbmw

The Covid-19 vaccine manufacturing failures at Emergent BioSolutions this year were the culmination of 30 years of frustrations. Our investigation dug into the forgotten history that led here. nytimes.com/2021/12/23/us/… w/Sheryl Gay Stolberg

Nice Nieman Storyboard interview with Jim Morris -- fellow The Center for Public Integrity alumnus, legendary reporter and beard aficionado -- about launching a nonprofit investigative news outlet (Public Health Watch) during a pandemic: niemanstoryboard.org/stories/a-star…

For anyone looking for a good read on a timely subject, might I suggest my former The Center for Public Integrity colleague Ronnie Greene's new book Heart of Atlanta: chicagoreviewpress.com/heart-of-atlan… It's the human story behind one of the most underappreciated Supreme Court civil rights cases.

Overlooked No More: Elizabeth Hayes, the coal town doctor who fought for miners' health: nytimes.com/2022/04/01/obi… Appreciation to Steven Greenhouse for telling the story.

Newly released documents show: McKinsey consultants worked for both Purdue Pharma and its regulator, the F.D.A. The firm stressed its govt. connections when pitching pharma cos. -- "who we know and what we know." w/Walt Bogdanich Mike Forsythe 傅才德 Jennifer Valentino-DeVries nytimes.com/2022/04/13/bus…

Have a look at some of the documents we drew on to tell the story of McKinsey and its work for both opioid manufacturers and the F.D.A.: industrydocuments.ucsf.edu/drug/collectio… oversight.house.gov/news/press-rel…

Op-ed from a retired miner with black lung: Benefits in jeopardy w/out action by Congress. "I am absolutely counting on Manchin to get this done." wvgazettemail.com/opinion/op_ed_… I had the privilege of speaking with Arvin for my book. His predicament hasn't dampened his jovial optimism.

In a hearing today, McKinsey's top executive apologized for the firm's work for opioid manufacturers. Members of Congress called his words hollow and referred to the $86 million McKinsey received from Purdue Pharma as "blood money." w/Mike Forsythe 傅才德 Walt Bogdanich

Amid withering questioning from members of Congress, McKinsey's top executive maintained that simultaneously serving both Purdue Pharma and its chief regulator, the F.D.A., was not a conflict of interest. nytimes.com/2022/04/27/bus…

EXCLUSIVE: As part of its 2021 settlement with US states, McKinsey pledged to make public documents on its work with opioid makers going back more than a decade. The docs show the firm's advice extended well beyond Purdue Pharma. By Chris Hamby and me nytimes.com/2022/06/29/bus…

McKinsey's work for opioid makers went well beyond Purdue, a vast new trove of documents shows. The firm counseled companies at the core of the crisis. w/Mike Forsythe 傅才德 nytimes.com/2022/06/29/bus…

In addition to helping Purdue Pharma "turbocharge" OxyContin sales while overdoses were surging in America, consulting giant McKinsey simultaneously worked with other drugmakers to boost $$$ of even stronger opioids like Opana. Chris Hamby Mike Forsythe 傅才德 nytimes.com/2022/06/29/bus…

Peruse for yourself the 100,00-plus documents that Mike Forsythe 傅才德 & I used to tell the story of McKinsey's broader work for opioid manufacturers: industrydocuments.ucsf.edu/opioids/collec… Our story: nytimes.com/2022/06/29/bus…

Congratulations to Jim Morris and the crew Public Health Watch on a year of great investigative journalism: publichealthwatch.org/2022/08/14/phw…

These workers are slowly suffocating to death after fabricating engineered-stone countertops: publichealthwatch.org/2022/12/02/lun… Great work by Jim Morris @Multi_American Public Health Watch

Primed by glowing media coverage and aggressive advertising, many patients regard ketamine and its newfound at-home availability as akin to a miracle cure. But there are many unknowns -- and risks. An investigation by Chris Hamby The New York Times nytimes.com/2023/02/20/us/…

Pandemic-era telemedicine rule changes have made it much easier to take the mind-altering drug ketamine at home. Many mental health patients have benefited, but the industry's rapid growth has outpaced evidence of safety. nytimes.com/2023/02/20/us/…

To understand the at-home ketamine boom, I spoke with 40+ patients. Many called the drug profoundly helpful, but some described addiction and bladder problems -- known risks of recreational use that have been largely downplayed in the medical community. nytimes.com/2023/02/20/us/…